
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is forecasted to report slightly weaker earnings and revenue for the second quarter of 2026 compared to consensus estimates, but overall is expected to perform within its own guidance for the full year of 2026. The company has a strong portfolio of flagship drugs in various therapeutic areas and has made recent acquisitions to bolster its rare disease and oncology offerings. Upside risks include strong pipeline data and better-than-expected performance from current products. Downside risks include disappointing pipeline data and regulatory or pricing concerns. Investors should watch for updates on the adoption of key growth drivers and potential catalysts on the company's earnings conference call. With continued growth expected from the rare disease segment and potential for greater adoption of key products like Uplizna and Imdelltra in small cell lung cancer, Amgen's stock is expected to have upside potential, although there are some risks to consider.
Bears say
Amgen is poised for near-term growth with upcoming catalysts such as the potential approval of Dazodalibep and Tezspire. However, concerns about competitive positioning and the FDA's proposed withdrawal of Tavneos may hinder the company's long-term revenue potential. Additionally, while sales of Uplizna exceeded expectations, significant increases in revenue estimates may not be sustainable. These fundamental factors lead to a neutral outlook for AMGN's stock.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares